-
CNIPA Upholds Alynlam Pharmaceutical’s PCSK9 siRNA Patent Against Junshi Biosciences Challenge
•
The China National Intellectual Property Administration (CNIPA) has rejected a challenge filed by Junshi Biosciences (SHA: 688180) against a patent held by Alynlam Pharmaceutical (NASDAQ: ALNY), which is related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies. CNIPA’s decision to fully maintain Patent No. 561449, associated with application number…
-
Everest Medicines Partners with Kezar Life Sciences to Commercialize Zetomipzomib in Asia
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license agreement with US firm Kezar Life Sciences Inc. (NASDAQ: KZR) to develop and commercialize zetomipzomib, Kezar’s novel first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea, and Southeast Asia. This partnership aims to leverage the…
-
I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
•
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises Ltd, announcing the termination of their license and collaboration agreement concerning CD47 antibody compounds and products. The agreement, initially signed on September 3, 2020, and amended on August 15, 2022, will officially end on November…
-
Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China
•
France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval from the National Medical Products Administration (NMPA) in China for its drug Dupixent (dupilumab), which is now approved to treat prurigo nodosa (PN) in adults. This makes Dupixent the first and only drug approved for…
-
EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare
•
The EU Chamber of Commerce in China has released its bi-annual “European Business in China Position Paper 2023/2024,” which compiles recommendations from over 1,700 member companies. The document aims to foster constructive dialogue between Europe and China, enhancing engagement between European firms and Chinese stakeholders for mutual benefit. The paper…
-
Eli Lilly Sues US Sellers of Counterfeit Mounjaro Products
•
Pharmaceutical giant Eli Lilly (NYSE: LLY) has filed a lawsuit in the United States against medical spas, wellness centers, and compounding pharmacies that are selling unregistered products claiming to be Mounjaro (tirzepatide), the company’s GLP-1 agonist. Mounjaro has recently gained popularity for its off-label use as a weight-loss drug, prompting…
-
Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million
•
Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk (NYSE: NVO), have completed the acquisition of biopharmaceutical company Paratek Pharmaceuticals (NASDAQ: PRTK) this week. The acquisition solidifies the group’s position in the market and expands their portfolio with the addition of the antibiotic Nuzyra…
-
MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for the first half of 2023, showcasing impressive revenue growth of 19% year-on-year (YOY) to USD 493 million. The company also reported a 13% reduction in losses, totaling USD 220 million. This performance highlights the company’s…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
